Our group's aim is to improve the treatment and survival of children with neuroblastoma, medulloblastoma and rhabdomyosarcoma. The goal of our laboratory is to improve the treatment and survival of ...

A ‘TripAdvisor-style’ website that helps scientists choose the best small-molecule tools for their experiments has been greatly expanded to include expert reviews of hundreds of chemical probes that ...

Dr Caroline Furness is a Group Leader at the Institute of Cancer Research and a Consultant Paediatric/TYA Haematologist at the Royal Marsden Hospital. She specialises in the care of paediatric ...

Dr Furness completed her medical training at Cambridge and Oxford University and her PhD at the Institute of Cancer Research. She trained in clinical haematology at the Royal Marsden Hospital and ...

One year of treatment with the targeted drug olaparib improves long-term survival in women with high-risk, early-stage breast cancer with mutations in BRCA1 or BRCA2 genes, new results from a major ...

Image: (from left to right) Sally Clarke, Andrew Castle, Anthony Horowitz, Marjorie Coles and Adam Kay. Credit: Adam Duke Photography Christmas arrived in style as celebrities and guests got into the ...

We transformed care for advanced prostate cancer, by validating inhibitors of androgen production as an effective cancer treatment, and discovering and developing abiraterone, a life-extending ...

Sentinal4D, a spinout company from The Institute of Cancer Research, London, has been announced to the public – having closed its first round of funding and appointed its foundational leadership team.

The goal of our laboratory is to improve the treatment and survival of children with neuroblastoma, medulloblastoma and rhabdomyosarcoma, three paediatric solid tumours in which high-risk patient ...

It’s been a busy year here in the ICR’s Business and Innovation Office (BIO)! Here are just some of the things we’ve been excited about. The year started with news that Socius and Aviva have joined ...